NasdaqGM - Nasdaq Real Time Price USD

Tango Therapeutics, Inc. (TNGX)

Compare
3.0600 +0.2100 (+7.37%)
At close: December 13 at 4:00:01 PM EST
3.0500 -0.01 (-0.33%)
After hours: December 13 at 7:42:01 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
43,383.0000
36,527.0000
24,860.0000
37,042.0000
7,656.0000
Operating Expense
183,081.0000
150,700.0000
135,931.0000
95,232.0000
59,856.0000
Operating Income
-139,698.0000
-114,173.0000
-111,071.0000
-58,190.0000
-52,200.0000
Net Non Operating Interest Income Expense
8,313.0000
6,619.0000
1,456.0000
495.0000
108.0000
Other Income Expense
8,196.0000
5,944.0000
1,493.0000
-248.0000
120.0000
Pretax Income
-123,189.0000
-101,610.0000
-108,122.0000
-57,943.0000
-51,972.0000
Tax Provision
206.0000
134.0000
54.0000
292.0000
--
Net Income Common Stockholders
-123,395.0000
-101,744.0000
-108,176.0000
-58,235.0000
-51,972.0000
Diluted NI Available to Com Stockholders
-123,395.0000
-101,744.0000
-108,176.0000
-58,235.0000
-51,972.0000
Basic EPS
-1.15
-1.08
-1.23
-0.94
-0.59
Diluted EPS
-1.15
-1.08
-1.23
-0.94
-0.59
Basic Average Shares
107,863.8560
94,572.4480
87,820.0370
62,108.0320
87,474.2580
Diluted Average Shares
107,863.8560
94,572.4480
87,820.0370
62,108.0320
87,474.2580
Total Operating Income as Reported
-139,698.0000
-114,173.0000
-111,071.0000
-58,190.0000
-52,200.0000
Total Expenses
183,081.0000
150,700.0000
135,931.0000
95,232.0000
59,856.0000
Net Income from Continuing & Discontinued Operation
-123,395.0000
-101,744.0000
-108,176.0000
-58,235.0000
-51,972.0000
Normalized Income
-123,395.0000
-101,744.0000
-108,176.0000
-58,235.0000
-51,972.0000
Interest Income
8,313.0000
6,619.0000
1,456.0000
495.0000
108.0000
Net Interest Income
8,313.0000
6,619.0000
1,456.0000
495.0000
108.0000
EBIT
-139,698.0000
-114,173.0000
-111,071.0000
-58,190.0000
-52,200.0000
EBITDA
-137,202.0000
-111,758.0000
-109,463.0000
-57,293.0000
-51,482.0000
Reconciled Depreciation
2,496.0000
2,415.0000
1,608.0000
897.0000
718.0000
Net Income from Continuing Operation Net Minority Interest
-123,395.0000
-101,744.0000
-108,176.0000
-58,235.0000
-51,972.0000
Normalized EBITDA
-137,202.0000
-111,758.0000
-109,463.0000
-57,293.0000
-51,482.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
--
12/31/2020 - 9/3/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INZY Inozyme Pharma, Inc.
3.0300
+1.68%
 
TCRX TScan Therapeutics, Inc.
2.8500
-5.63%
 
TYRA Tyra Biosciences, Inc.
14.94
-1.52%
 
ORIC ORIC Pharmaceuticals, Inc.
8.52
+1.07%
 
RLAY Relay Therapeutics, Inc.
4.7100
-1.46%
 
CRGX CARGO Therapeutics, Inc.
13.74
-8.03%
 
FDMT 4D Molecular Therapeutics, Inc.
6.50
-5.52%
 
ERAS Erasca, Inc.
2.5600
-2.66%
 
FHTX Foghorn Therapeutics Inc.
5.30
-8.30%
 
KURA Kura Oncology, Inc.
9.63
-0.62%